PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023GlobeNewsWire • 10/09/23
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology PlatformGlobeNewsWire • 10/04/23
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/22/23
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of HealthGlobeNewsWire • 09/21/23
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀GlobeNewsWire • 09/19/23
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/09/23
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023GlobeNewsWire • 07/26/23
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site InfectionsGlobeNewsWire • 06/29/23
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site InfectionsGlobeNewsWire • 06/22/23
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital MarketGlobeNewsWire • 06/05/23
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site InfectionsGlobeNewsWire • 05/22/23
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/10/23
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023GlobeNewsWire • 04/26/23
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceGlobeNewsWire • 04/14/23
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross ProceedsGlobeNewsWire • 03/31/23
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded WarrantsGlobeNewsWire • 03/29/23
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/08/23